Cardiometabolic Outcomes With Light Exposure During Sleep

Light Clinical Trial

Official title:

Cardiometabolic Outcomes With Light Exposure During Sleep

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05317559
• Other study ID #: STU00094737
• Status: Completed
• Phase: N/A
• Start date: February 2014
• Est. completion date: July 2018

Study information

• Verified date: March 2022
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study tested the hypothesis that acute exposure to light during nighttime sleep adversely affects cardiometabolic function.

Description:

This study tested the hypothesis that acute exposure to light during sleep adversely affects next morning glucose homeostasis and whether this effect occurs via reduced sleep quality, melatonin suppression, or sympathetic nervous system (SNS) activation during sleep. Twenty young adults participated in this parallel-group study design. The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: July 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• healthy adults

• ages 18-40 years

• habitual sleep duration of 6.5-8.5 hours

• habitual sleep onset of 9:00 pm-1:00 am

Exclusion Criteria:

• any sleep disorder as assessed by history and screening questionnaires for obstructive sleep apnea (Berlin) and excessive daytime sleepiness (ESS >12), and by PSG to exclude sleep apnea (apnea hypopnea index = 15), periodic leg movements (movement arousal index = 15), or REM sleep behavior disorder;

• history of a cognitive or neurological disorder;

• history of a major psychiatric disorder, including but not limited to mood/anxiety, eating, and alcohol/substance abuse disorders;

• depressed mood (Beck Depression Inventory II score = 20);

• diabetes or other endocrine disorders;

• any gastrointestinal disease requiring dietary adjustment;

• blindness or significant vision loss;

• any unstable or serious medical conditions;

• current or recent (within the past month) of psychoactive, hypnotic, stimulant or analgesic medications;

• shift work or other types of self-imposed irregular sleep schedules;

• obesity (body mass index > 30 kg/m2);

• history of habitual smoking (6 or more cigarettes per week) or drinking (7 or more alcoholic beverages per week) or caffeine consumption greater than 300 mg per day;

• current use of light therapy;

• use of any other legal or illicit substance that may affect sleep and/or appetite;

• allergy to heparin.

• Due to the metabolic stress associated with pregnancy and breastfeeding, patients who were pregnant or breastfeeding were also excluded.

Related Conditions & MeSH terms

• Light

Intervention

Behavioral:
• room light
The room light condition (n=10) included one night of sleep in dim light (< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Northwestern University

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Melatonin	pg/ml	Day 2
Other	Melatonin	pg/ml	Day 3
Other	subjective sleepiness	sleepiness level	Day 2
Other	subjective sleepiness	sleepiness level	Day 3
Other	hunger	hunger level	Day 2
Other	hunger	hunger level	Day 3
Primary	Matsuda Index	OGTT	Day 2
Primary	Matsuda Index	OGTT	Day 3
Primary	HOMA-IR	Fasting	Day 2
Primary	HOMA-IR	Fasting	Day 3
Secondary	Sleep Stages	Stage N1, N2, N3	Night 1
Secondary	Sleep Stages	Stage N1, N2, N3	Night 2
Secondary	Sleep Stages	Stage N1, N2, N3	Night 3
Secondary	Heart Rate	beat to beat	Night 2
Secondary	Heart Rate	beat to beat	Night 3
Secondary	Blood pressure	diastolic/systolic	Day 2
Secondary	Blood pressure	diastolic/systolic	Day 3
Secondary	Slow Wave Activity	Spectral power in the Slow Wave Activity (0.5 to 4 Hz)	Night 1
Secondary	Slow Wave Activity	Spectral power in the Slow Wave Activity (0.5 to 4 Hz)	Night 2
Secondary	Slow Wave Activity	Spectral power in the Slow Wave Activity (0.5 to 4 Hz)	Night 3